ROLVEDON

This brand name is authorized in United States.

Active ingredients

The drug ROLVEDON contains one active pharmaceutical ingredient (API):

1	Eflapegrastim UNII UT99UG9QJX - EFLAPEGRASTIM
	Eflapegrastim-xnst is a recombinant human granulocyte growth factor that binds to G-CSF receptors on myeloid progenitor cells and neutrophils, triggering signaling pathways that control cell differentiation, proliferation, migration and survival. Eflapegrastim-xnst has been shown to elevate neutrophil counts in healthy subjects and in cancer patients.
	Read more about Eflapegrastim

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ROLVEDON Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA19		L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	76961-101